Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1354744-91-4C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)OMNYIRXLCPODKLG-VUTNLTPYSA-NSee also: Naloxegol (annotation moved to).
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Naloxegol oxalate
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
NALOXEGOL OXALATE
Opioid Antagonists [MoA]; Opioid Antagonist [EPC]
BeschreibungNaloxegol oxalate (XXI) is a peripherally acting μ-opioid receptor antagonist that was approved in the USA and EU for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug, a pegylated version of naloxone, has significantly reduced central nervous system (CNS) penetration and works by inhibiting the binding of opioids in the gastrointestinal tract. Naloxegol oxalate was developed by Nektar and licensed to AstraZeneca. Although we were unable to find a single report in the primary or patent literature that describes the exact experimental procedures to prepare naloxegol oxalate, there have been reports on the preparation of closely related analogs with specific reports on improving the selectivity of the reduction step156 and the salt formation of the final drug substance.
VerwendenNaloxegol Oxalate is an oxalate form of Naloxegol (N284470) which is a peripherally-selective opioid antagonist.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
1354744-91-4DTXSID50159395CHEMBL2219416